Literature DB >> 22493603

A Case of Carcinoid Tumor-Associated Hypercalcemia.

Fadi Siyam1, Obai Abdullah, Michael Gardner, Stephen Brietzke, James Sowers.   

Abstract

Hypercalcemia as a complication of carcinoid tumors is extremely rare. Accordingly, we report the case of a 55-year-old male with metastatic carcinoid tumor and hypercalcemia, which corrected when the patient was treated with octreotide for symptomatic relief of watery diarrhea. The etiology of the hypercalcemia is presumed to be a neoplastic expression of fibroblast growth factor-23, which was found to be inappropriately high-to-normal when other factors such as parathyroid hormone, calcitonin and vitamin D were appropriately low or low-to-normal.

Entities:  

Year:  2012        PMID: 22493603      PMCID: PMC3318931          DOI: 10.1159/000335673

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  18 in total

Review 1.  Molecular mechanisms of bone metastasis and therapeutic implications.

Authors:  Regis J O'Keefe; Theresa A Guise
Journal:  Clin Orthop Relat Res       Date:  2003-10       Impact factor: 4.176

Review 2.  Current status of gastrointestinal carcinoids.

Authors:  Irvin M Modlin; Mark Kidd; Igor Latich; Michelle N Zikusoka; Michael D Shapiro
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

3.  Intractable hypercalcaemia due to parathyroid hormone-related peptide secretion by a carcinoid tumour.

Authors:  C S Mantzoros; L J Suva; A C Moses; R Spark
Journal:  Clin Endocrinol (Oxf)       Date:  1997-03       Impact factor: 3.478

4.  Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide.

Authors:  M Barhoum; L Hutchins; V A Fonseca
Journal:  Am J Med Sci       Date:  1999-09       Impact factor: 2.378

5.  Phosphate Metabolism in Cardiorenal Metabolic Disease.

Authors:  Deepashree Gupta; Stephen Brietzke; M R Hayden; L Romayne Kurukulasuriya; James R Sowers
Journal:  Cardiorenal Med       Date:  2011-10-13       Impact factor: 2.041

6.  Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism.

Authors:  Ravinder J Singh; Rajiv Kumar
Journal:  Mayo Clin Proc       Date:  2003-07       Impact factor: 7.616

Review 7.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia.

Authors:  W A Ratcliffe; A C Hutchesson; N J Bundred; J G Ratcliffe
Journal:  Lancet       Date:  1992-01-18       Impact factor: 79.321

9.  Hypercalcaemia caused by a carcinoid tumour.

Authors:  M M Brzozowska; L Wolmarans; J V Conaglen
Journal:  Intern Med J       Date:  2009-06       Impact factor: 2.048

10.  Multiple endocrine neoplasia type 1 accompanied by duodenal carcinoid tumors and hypergastrinemia: a familial case.

Authors:  K Sugimoto; S Oosawa; T Furuta; H Arai; Y Sato; M Ikuma; M Yamada; M Suzuki; H Hanai; E Kaneko
Journal:  Intern Med       Date:  1995-07       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.